Published in J Neurochem on June 01, 1972
Dopa decarboxylase activity of the living human brain. Proc Natl Acad Sci U S A (1991) 1.06
Relationship of striatal dopamine synthesis capacity to age and cognition. J Neurosci (2008) 1.05
Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. PLoS One (2012) 0.80
Relation between dopamine synthesis capacity and cell-level structure in human striatum: a multi-modal study with positron emission tomography and diffusion tensor imaging. PLoS One (2014) 0.78
Chromatographic analysis of age-related changes in mucosal serotonin transmission in the murine distal ileum. Chem Cent J (2012) 0.77
Influence of O-methylated metabolite penetrating the blood-brain barrier to estimation of dopamine synthesis capacity in human L-[β-(11)C]DOPA PET. J Cereb Blood Flow Metab (2013) 0.76
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci (1973) 7.85
Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med (1988) 4.98
Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev (1966) 4.55
Dopa-responsive dystonia: pathological and biochemical observations in a case. Ann Neurol (1994) 2.88
Cortical-basal ganglionic degeneration. Neurology (1990) 2.04
Biochemical pathophysiology of Parkinson's disease. Adv Neurol (1987) 1.87
Kainic acid induced seizures: neurochemical and histopathological changes. Neuroscience (1983) 1.75
Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions. Science (1970) 1.62
Effects of morphine on striatal dopamine metabolism: possible mechanism of its opposite effect on locomotor activity in rats and mice. Eur J Pharmacol (1974) 1.60
Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature (1978) 1.52
Technetium-99m-d,1-hexamethylpropyleneamine oxime (HMPAO) uptake and glutathione content in brain tumors. J Nucl Med (1991) 1.48
Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. N Engl J Med (1981) 1.48
Dopamine in the basal ganglia. Its role and therapeutic implications (including the clinical use of L-DOPA). Br Med Bull (1973) 1.47
Brain neurotransmitter changes in three patients who had a fatal hyperthermia syndrome. Am J Psychiatry (1990) 1.43
The mechanisms of action of L-dopa in Parkinson's disease. Life Sci (1974) 1.42
Hereditary form of parkinsonism--dementia. Ann Neurol (1998) 1.39
Reversible drug-induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol (1982) 1.36
Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol (1995) 1.34
Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology (1996) 1.30
The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther (1975) 1.28
[Homovanillic acid in the cerebrospinal fluid: studies in Parkinson's syndrome and other diseases of the CNS]. Wien Klin Wochenschr (1966) 1.26
Globus pallidus dopamine and Parkinson motor subtypes: clinical and brain biochemical correlation. Neurology (2008) 1.22
Upregulation of gamma-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J Pharmacol Exp Ther (1985) 1.20
Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology (1998) 1.19
Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther (1986) 1.19
Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia. Neurology (1999) 1.16
Morphine catalepsy in the rat: relation to striatal dopamine metabolism. Eur J Pharmacol (1972) 1.14
Parkinson's disease: from brain homogenate to treatment. Fed Proc (1973) 1.14
Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem (1992) 1.13
Elevated levels of DeltaFosB and RGS9 in striatum in Parkinson's disease. Biol Psychiatry (2001) 1.12
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience (1991) 1.12
Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties. J Pharmacol Exp Ther (1988) 1.10
Alterations of GABA-mediated synaptic transmission in human epilepsy. Adv Neurol (1986) 1.08
Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation. Neurology (2000) 1.05
GTP-cyclohydrolase I gene mutations in hereditary progressive amd dopa-responsive dystonia. Ann Neurol (1996) 1.04
Quinolinic-phosphoribosyl transferase activity is decreased in epileptic human brain tissue. Epilepsia (1988) 1.01
Ifenprodil and SL 82.0715 as cerebral antiischemic agents. III. Evidence for antagonistic effects at the polyamine modulatory site within the N-methyl-D-aspartate receptor complex. J Pharmacol Exp Ther (1990) 1.01
Kainic acid-induced seizures: dose-relationship of behavioural, neurochemical and histopathological changes. Brain Res (1985) 1.00
Brain neurotransmitters in dystonia musculorum deformans. N Engl J Med (1986) 1.00
Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser (1975) 1.00
A model for the quantitative study of central dopaminergic and serotoninergic activity. Eur J Pharmacol (1972) 0.99
Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine. Adv Biochem Psychopharmacol (1978) 0.97
Sulphasalazine and PhCL28A inhibit the formation of ethanol- and phenylbutazone-induced rat gastric ulcers: lack of involvement of endogenous prostaglandins? Br J Pharmacol (1988) 0.97
Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res (1994) 0.97
Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter markers. Ann Neurol (1985) 0.96
Serotonin and 5-hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients. Adv Biochem Psychopharmacol (1974) 0.96
Kainic acid-induced changes of serotonin and dopamine metabolism in the striatum and substantia nigra of the rat. Eur J Pharmacol (1981) 0.96
The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonism. Parkinsonism Relat Disord (1998) 0.96
Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett (1985) 0.95
L-glutamic acid decarboxylase in Parkinson's disease: effect of L-dopa therapy. Nature (1973) 0.95
Chronic antidepressants and GABA "B" receptors: a GABA hypothesis of antidepressant drug action. Life Sci (1984) 0.95
GABA involvement in neuroleptic-induced catalepsy. J Pharm Pharmacol (1978) 0.94
Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? Ann Neurol (1995) 0.93
gamma-Aminobutyric acid (GABA) receptor stimulation. II. Specificity of progabide (SL 76002) and SL 75102 for the GABA receptor. J Pharmacol Exp Ther (1982) 0.93
The cyclooxygenase and lipoxygenase inhibitor BW755C protects rats against kainic acid-induced seizures and neurotoxicity. Brain Res (1994) 0.92
Dementia, parkinsonism, and motor neuron disease: neurochemical and neuropathological correlates. Ann Neurol (1988) 0.92
Familial fatal Parkinsonism with alveolar hypoventilation and mental depression. Ann Neurol (1979) 0.91
Pharmacological and behavioral profile of alpidem as an anxiolytic. Pharmacopsychiatry (1990) 0.91
Neurotransmitter interactions related to central dopamine neurons. Essays Neurochem Neuropharmacol (1978) 0.91
Striatonigral degeneration. Response to levodopa therapy with pathological and neurochemical correlation. J Neurol Sci (1973) 0.91
CNS compensation to dopamine neuron loss in Parkinson's disease. Adv Exp Med Biol (1977) 0.90
Occurrence and distribution of L-DOPA decarboxylase in the human brain. Brain Res (1970) 0.90
Cerebral cortex Gs alpha protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem (1993) 0.90
Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence. Annu Rev Pharmacol Toxicol (1977) 0.90
The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci Lett (1988) 0.89
Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum. Ann Neurol (1987) 0.89
Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Parkinsonism Relat Disord (1998) 0.89
gamma-Aminobutyric acid (GABA) receptor stimulation. III. Effect of progabide (SL 76002) on norepinephrine, dopamine and 5-hydroxytryptamine turnover in rat brain areas. J Pharmacol Exp Ther (1982) 0.88
gamma-Aminobutyric acid (GABA) receptor stimulation. I. Neuropharmacological profiles of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectra. J Pharmacol Exp Ther (1982) 0.88
[Decreased homovanillic acid concentration in the brain in parkinsonian subjects as an expression of a disorder of central dopamine metabolism]. Klin Wochenschr (1965) 0.88
The role of brain edema in epileptic brain damage induced by systemic kainic acid injection. Neuroscience (1984) 0.88
Beneficial effects of serotonin precursors in postanoxic action myoclonus. Neurology (1976) 0.87
Distribution of choline acetyltransferase and glutamate decarboxylase within the substantia nigra and in other brain regions from control and Parkinsonian patients. J Neurochem (1975) 0.87
Sensitization of dopamine-stimulated adenylyl cyclase in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson's disease. J Neurochem (1992) 0.87
Neurochemical pathology and pharmacology of brain dopamine and acetylcholine: rational basis for the current drug treatment of Parkinsonism. Contemp Neurol Ser (1971) 0.87
Neurochemical basis of dementia in Parkinson's disease. Can J Neurol Sci (1984) 0.86
Imbalance of brain monoamines and clinical disorders. Prog Brain Res (1982) 0.86
Distribution of high affinity sodium-independent [3H]gamma-aminobutyric acid [3H]GABA binding in the human brain: alterations in Parkinson's disease. Brain Res (1977) 0.86
Elevated gamma-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss. Ann Neurol (1986) 0.86
Brain neurotransmitter changes in human narcolepsy. Neurology (1992) 0.85
Noradrenaline distribution insubcortical areas of the human brain. Brain Res (1977) 0.85
Antiproliferative action of dopamine and norepinephrine in neuroblastoma cells expressing the human dopamine transporter. FASEB J (2001) 0.85
Cerebellar norepinephrine in patients with Parkinson's disease and control subjects. Arch Neurol (1984) 0.85
[Dopamine metabolism in the rabbit caudate nucleus following partial inhibition of brain monoamine oxidase by nialamide]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 0.85
Parkinson's disease and its chemotherapy. Biochem Pharmacol (1975) 0.85
The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav (1983) 0.85
Neurohumoral interactions and basal ganglia function and dysfunction. Res Publ Assoc Res Nerv Ment Dis (1976) 0.85
[3H]vesamicol binding in human brain cholinergic deficiency disorders. Neurosci Lett (1990) 0.85
Chronic exposure to manganese decreases striatal dopamine turnover in human alpha-synuclein transgenic mice. Neuroscience (2011) 0.85
[The influence of diethyldithiocarbamate on cerebral catecholamine, spontaneous activity and L-DOPA hyperactivity]. Med Pharmacol Exp Int J Exp Med (1967) 0.84
Dopamine in thelimbic regions of the human brain: normal and abnormal. Adv Biochem Psychopharmacol (1977) 0.84
Acetylcholine release within the cat striatum during the sleep-wakefulness cycle. Nature (1973) 0.84
L-DOPA treatment in Parkinson's disease: effect on dopamine and related substances in discrete brain regions. Experientia (1971) 0.84
The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study. Neurobiol Dis (2012) 0.84
Role of glucocorticoids in the cholinergic degeneration in rat hippocampus induced by ethylcholine aziridinium (AF64A). J Neurosci (1993) 0.84